Call to Action

A call for urgent action: A renewed commitment to gender-responsive research for health equity and human rights in the context of COVID-19 pandemic

GENEVA, 17 APRIL 2020 – On the 11th March 2020, the World Health Organization (WHO) declared the outbreak of the novel coronavirus (COVID-19) a pandemic. Only four months into the unprecedented global health crisis, we have witnessed the spread of COVID-19 to nearly every corner of the world. The rapidly changing geography of the pandemic has uncovered many challenges that the global community is learning to address.

Our governments and communities have directed response efforts at saving lives and preventing further spread. The global research community has responded with an unprecedented speed in advancing knowledge about the virus and pressing to develop diagnostics, therapeutics and vaccines. These efforts while critical and welcome must account for gender and its intersections with other social markers in order to understand the equity and human rights implications of COVID-19. In the urgency to generate evidence and discover preventive or therapeutic tools to curb the pandemics, we cannot compromise the standard of rigorous and robust research. The emerging body of literature on COVID-19 illustrates that sex and gender across life course are generally being disregarded, despite evidence showing they play a significant role in shaping risks of illness, death or other harms, restricting better understanding of the disease and its impact on lives and livelihoods.

Although attention to the gendered social, economic, and human rights repercussions as well as other health impacts, which deem to be harsh and long-lasting, is growing, evidence on these indicators has so far been scarcely available. This would be necessary to inform mitigation strategies and ensure that all people regardless of gender, age, ethnicity, socioeconomic status, nationality, sexual orientation, gender identity, migratory or any other status have equitable access to testing, quality respectful treatment, social and economic support measures to minimise the damaging consequences.

We have a collective responsibility to shape the trajectory of our present and future efforts to fight global pandemics. With this in mind, GENDRO calls to promote generation of gender-sensitive evidence and forms of knowledge to create more equitable solutions to mitigate the multiple impacts of COVID-19 on women, men and gender diverse persons across all sectors and layers of society. GENDRO welcomes everyone interested in the subject to join our call for action and maintain the momentum to appeal all those involved directly and indirectly in COVID-19 response to act urgently and responsibly:

1. Sex- and age-disaggregated data on COVID-19 must be systematically collected and reported and research must be designed and conducted in a way to allow meaningful gender analysis of safety, efficacy and effectiveness of diagnosis tools, drug or vaccine candidates.

Evidence to date points to gender and age differences in terms of susceptibility and vulnerability to infection, disease progression and outcome. Yet, reported data on incidence, prevalence, symptoms, testing, hospitalisation, ICU care, discharge, recovery or mortality are not systematically provided, nor broken down by sex and age, thus hamper a better understanding of disease and effective policy and programmatic efforts. Our knowledge about the gender and age breakdown of the growing number of infected health workers remains also limited. Furthermore, any ongoing health research, including but not limited to preclinical studies and clinical trials, must be designed to adequately capture sex and gender differences in different age groups and examine the gender implications. Recruitment strategies for trials will need to ensure gender balance of participants to make such analysis feasible.

2. Data analysis and research on social, economic and human rights impact of COVID-19 must systematically consider gender and other dimensions of inequality.

​Data collected on access to quality, affordable and equitable healthcare, or on the impact of the quarantine measures on employment rates, gender-based violence, mental health, access to other essential services e.g., sexual and reproductive health services, financial support measures, social protection measures, human rights, or any other indicators must be gender sensitive and be disaggregated by sex and age, as a minimum, to allow for identification of gender and other disparities and devise more equitable mitigation strategies. Ideally, data should also be stratified by other dimensions of inequality, such as ethnicity, refugee status, gender identity, sexual orientation, and disability to identify and address other inequities. Research on social, economic and human rights implications of COVID-19 must equally apply an intersectional gender lens to account for the differential impact of the epidemic of all genders across different layers of the society. Dedicated research must also be carried out to understand the implications on underserved and populations that are underrepresented in research.

3. Peer-reviewed publications of COVID-19 related research must present all data disaggregated by sex and age and articulate other gender considerations.

​Editors of scientific journals must require authors submitting research and analysis related to COVID-19 to provide all data (for example, data on recruitment, enrolment, dropouts, retention, completion, adverse effects and all outcomes in clinical trials) disaggregated by sex and age, as a minimum, as suggested by the Sex and Gender Equity in Research (SAGER) guidelines. The fully disaggregated data could be published as part of the article or as supplementary material easily accessible online. Policy research and other research in social, political, economic, and data sciences must report how gender and its intersection with other social markers have been accounted for. All authors should be encouraged to analyse and report any gender implications and justify lack of any such analysis.

4. Research funding agencies and ethics committees must be diligent in ensuring a gender sensitive approach to research.

​As key gatekeepers in the research ecosystem, research funding agencies and research ethics committees play an instrumental role in ensuring rigorous and ethical research that benefits all. Hence, they need to continuously emphasise the importance of integration of gender and age dimensions in any research related to COVID-19 and encourage consideration of other important dimensions in research proposals and protocols.

GENDRO continues to observe and monitor publications that address the gendered implications of COVID-19 and we share these on our social media and our website. GENDRO encourages information exchange among and beyond GENDRO’s Gender, Evidence and Health Network. We must be cautious of premature and misleading information and gender-blind interpretations. We must be vigilant that research and analysis are transparent, complete and accessible in a timely fashion to allow for critical examination and scrutiny of information. Now as never before we need robust research and data to address the pressing global health challenges.

Endorse our call for action for a stronger commitment to gender-sensitive and responsive research in the context of novel coronavirus pandemic.

Endorse our call for action for a stronger commitment to gender-sensitive and responsive research in the context of novel coronavirus pandemic.

Online endorsees …

NameAffiliation

Deepa

Pindolia

WHO

Atta

Ul Haq

Youth Association for Development (YAD) Pakistan

Mariela

Infante Erazo

Corporación Humanas Chile

Angèle

Gayet-Ageron

University Hospitals of Geneva & University of Geneva

Gizele

Martins

UFRJ

Maria Isabelle

Wieser

foraus - Forum on Foreign Policy

Amy

Vassallo

The George Institute for Global Health

PATRICIA

SILVEYRA

Indiana University Bloomington

Faith

Nganyi

Sciences Po

Marygorety

Otieno

African Womens' Studies Centre

Fern

Terris-Prestholt

London School of Hygiene and Tropical Medicine

Lavanya

Vijayasingham

United Nations University Interational Institute for Global Health

Claudia

Lopes

United Nations University IIGH

Abha

Saxena

Independent Bioethics Advisor

Renée

Hunter

Value for Women

Katharina

O'Cathaoir

Faculty of Law, University of Copenhagen

Hilary

Homans

Prof. Dr.

Pavel

Ovseiko

University of Oxford

Chantal

BINWA

AFPDE DR CONGO

Maria Helen

Dayo

University of the Philippines Los Baños

Hulya

Simga

Maltepe University (Turkey), Center for Women and Family Studies

Bijoya

Roy

Centre for Women's Development Studies

Mary

Showstark

International Federation of Physician Assistant/Physician Associate and Clinical Officer/Clinical Associate/Comparable Students’ Association (IFPACS)

Ravi

Ram

PHM

Anny

Torres

Ufop

Lidia

Arroyo

UOC

Nancy

Clark

University of Victoria

Yana

Daneva

GENDRO

Fiona

Samuels

ODI

Sarah

Simpson

EquiACT, independent consultancy

Maria D

Rodriguez Frias

UAH, Madrid

Beata

Bielska

Nicolaus Copernicus University in Torun

Thomas

Berghöfer

DESY Hamburg

Kamal

Shah

KPMG - International Development Advisory Services (IDAS)

Andrea

Tricco

Unity health toronto

Flynn

Lebus

FSG

Kelly

Thompson

The George Institute for Global Health

Akarsh

Venkatasubramanian

Global Health Centre, IHEID

Pallavi

Mathur

Bhartiya Skill Development University

Michael

Ewers

Ludwig Maximilian University

Lidia

Arroyo

Open University of Catalonia

Paola

De Castro

Istituto Superiore di Sanità

Shirin

Heidari

GENDRO

Maria

Halkias

GENDRO

Mona

Loutfy

University of Toronto

David

Haerry

Positive Council Switzerland

Leila

Garcia

Institute of Applied Economic Research, Brazil

Juan

Alguacil

Full Professor of Public Health

Meg

Davis

Graduate Institute

Misghina

Weldegiorgis

Imperial College London

Claudia

Ahumada

Kristine

Hejgaard

Trusted advisor

Frederik

Schaltz-Buchholzer

University of Southern Denmark

Petra

Verdonk

Amsterdam UMC-VUmc

Roojin

Habibi

Global Strategy Lab

Jagnoor

Jagnoor

AVAC

AVAC

AVAC

Surekha

Garimella

The George Institute for Global Health, India

Manju

Chatani

Robyn

Norton

The George Institute for Global Health

Christine

Benn

University of Southern Denmark

Joanna

Pradela

IWDA IDM

Dominic

Kemps

Sommartel Ltd.

Alexandra

Calmy

Geneva University

Dominic

Eggel

IHEID

Martin

Tod

Men's Health Forum (GB)

Jenna

Haverfield

CIHR Institute of Gender and Health

Catherine

Hankins

Professor of Public and Population Health, Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, McGill University, Montreal

Dina

Balabanova

London School of Hygiene and Tropical Medicine

Ghazal

Zaboli

Science Teacher

Jill

Gay

Chief Technical Officer What Works Association USA

Mark

Woodward

The George Institute for Global Health, University of Oxford

Sofia

Ahmed

University of Calgary

Erik

VÃ…GBERG

Non-profit

Rasa

Valantinaite

Lydia

Mungherera

Gender Consult

Tyler

Crone

ATHENA Network

Victoria

Prieto-Echagüe

Institut Pasteur de Montevideo

Stephen

Burrell

Durham University

Sabine

Oertelt-Prigione

Radboud University, Nijmegen, NL

Rosemary

Morgan

Johns Hopkins Bloomberg School of Public Health

Geordan

Shannon

UCL

Petra

Verdonk

Amsterdam UMC dept Medical Humanities

MILKA

DINEV

REPRODUCTIVE HEALTH SUPPLIES COALITION

cem

uzun

Prof. Dr.

Marta

Rondon

INSTITUTO NACIONAL MATERNO PERINATAL AND UNIVERSIDAD PERUANA CAYETANO HEREDIA, LIMA PERU

Teresa

Ruiz-Cantero

Professor of Preventive Medicine and Public Health, University of Alicante, Spain

carol

Tyroler

Gender Expert

Megan

Holloway

Vivienne C.

Bachelet

Medwave; Universidad de Santiago de Chile (USACH)

Niyati

Shah

Joël

Graf

Euresearch

Peter

Baker

Director, Global Action on Men's Health

Ineke

Klinge

Cara

Tannenbaum

Scientific Director, Institute of Gender and Health, Canadian Institutes of Health Research

Ioannis

Rouvelas

Karolinska Institutet, Sweden

Alice

Welbourn

Salamander Trust